Biogen (NASDAQ: BIIB) director granted 1,505-share equity compensation award

Rhea-AI Filing Summary

BIOGEN INC. director William A. Hawkins reported an equity compensation award rather than an open-market trade. He acquired 1,505 shares of Common Stock at no cost under a grant classified as a “grant, award, or other acquisition.”

After this award, Hawkins directly holds 10,365 Common Stock shares. According to a footnote, the related restricted stock units vest on the earlier of the next annual meeting or the anniversary of the date of grant of June 9, 2026, tying this award to his ongoing board service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HAWKINS WILLIAM A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,505	$0.00	--

Holdings After Transaction: Common Stock — 10,365 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity award: 1,505 shares Award price: $0.00 per share Holdings after grant: 10,365 shares

3 metrics

Equity award 1,505 shares Common Stock grant to director on June 9, 2026

Award price $0.00 per share Grant, award, or other acquisition classification

Holdings after grant 10,365 shares Total direct Common Stock held by Hawkins after transaction

Key Terms

restricted stock units, grant, award, or other acquisition, Common Stock, non-derivative

4 terms

restricted stock units financial

"The restricted stock units vest on the earlier of (i) the next annual meeting..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type": "non-derivative""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAWKINS WILLIAM A

(Last) (First) (Middle)

BIOGEN INC.

225 BINNEY ST.

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		1,505(1)	A	$0	10,365	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.

	/s/ Wendell Taylor, Attorney in Fact for William Allen Hawkins III	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Biogen (BIIB) director William A. Hawkins report?

Biogen director William A. Hawkins reported an equity compensation award of 1,505 Common Stock shares. The filing classifies this as a grant, award, or other acquisition, not an open-market purchase or sale.

How many Biogen (BIIB) shares did William A. Hawkins acquire in this Form 4?

William A. Hawkins acquired 1,505 shares of Biogen Common Stock at a price of $0.00 per share. The transaction is recorded as a non-derivative grant, reflecting board-related equity compensation rather than a market transaction.

What are William A. Hawkins’ Biogen (BIIB) holdings after this transaction?

After the grant, William A. Hawkins directly holds 10,365 shares of Biogen Common Stock. This total includes the 1,505-share award reported in the filing and reflects his updated direct ownership position as of the transaction date.

How do the Biogen (BIIB) restricted stock units granted to Hawkins vest?

The restricted stock units vest on the earlier of the next annual meeting or the anniversary of the date of grant of June 9, 2026. This means vesting is tied to future corporate governance timing and Hawkins’ continued board service.

Was the Biogen (BIIB) transaction by William A. Hawkins a market buy or sell?

The transaction was not a market buy or sell. It is coded as an acquisition under a grant, award, or other acquisition, with a $0.00 per-share price, indicating equity compensation rather than an open-market trade.